A Dose-Ranging Study of Intravenous BNZ132-1-40 in Patients With Large Granular Lymphocyte Leukemia or Refractory Cutaneous T‑Cell Lymphoma

Trial Profile

A Dose-Ranging Study of Intravenous BNZ132-1-40 in Patients With Large Granular Lymphocyte Leukemia or Refractory Cutaneous T‑Cell Lymphoma

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Aug 2017

At a glance

  • Drugs BNZ 1 (Primary)
  • Indications Cutaneous T cell lymphoma; Lymphoid leukaemia
  • Focus Adverse reactions
  • Sponsors Bioniz
  • Most Recent Events

    • 01 Aug 2017 Status changed from planning to not yet recruiting.
    • 07 Jul 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top